Vertex Pharmaceuticals Incorporated announced the FDA has approved expanded use of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a… read more.
Vertex Pharmaceuticals announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
